MNG
CRL icon

Manning & Napier Group’s Charles River Laboratories CRL Stock Holding History

Manning & Napier Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,959
Closed -$3.04M – 261
2022
Q4 		$3.04M Buy
+13,959
New +$3.05M 0.04% 237

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Manning & Napier Group's CRL Position: Q1 2023 in Review

Manning & Napier Group sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 13,959 shares — an estimated $3.04M sold.

Manning & Napier Group first reported a position in CRL in Q4 2022 and held it in 1 quarter. The position peaked at $3.04M in Q4 2022. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

  • Manning & Napier Group reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
  • Manning & Napier Group sold 13,959 Charles River Laboratories shares in Q1 2023, an estimated $3.04M.
  • Manning & Napier Group first reported a position in Charles River Laboratories in Q4 2022 and held it in 1 quarter.
  • Manning & Napier Group's Charles River Laboratories position peaked at $3.04M in Q4 2022.
  • 620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Manning & Napier Group's 13F filing for Q1 2023, filed 17 Apr 2023.